Empagliflozin retains benefits in 'True' HFpEF Patients - Video
|
Overview
Empagliflozin provides a wide range of benefits in patients with "true" heart failure and preserved ejection fraction (HFpEF) , meaning an LVEF of 50% or greater, EMPEROR-Preserved investigators report. The main results of the placebo-controlled trial, showed that the sodium-glucose cotransporter 2 (SGLT2) inhibitor lowers the risk of CV death/hospitalization for heart failure in patients with HFpEF.
But some commentators questioned whether EMPEROR-Preserved was truly a trial of HFpEF because it included patients with ejection fractions between 41% and 49%—considered "midrange" or "mildly reduced" in practice guidelines.
Speakers
Dr Prem Aggarwal, (MD Medicine, DNB Cardiology) is a Cardiologist by profession and also the Co-founder and Chairman of Medical. He focuses on news and perspectives about cardiology, and medicine related developments at Medical Dialogues. He can be reached out at drprem@medicaldialogues.in
Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751